HomeCompareOTIC vs SBUX

OTIC vs SBUX: Dividend Comparison 2026

OTIC yields 23529.41% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OTIC wins by $263656825893602263040.00M in total portfolio value
10 years
OTIC
OTIC
● Live price
23529.41%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$263656825893602263040.00M
Annual income
$261,470,826,952,048,300,000,000,000.00
Full OTIC calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — OTIC vs SBUX

📍 OTIC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOTICSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OTIC + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OTIC pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OTIC
Annual income on $10K today (after 15% tax)
$2,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$222,250,202,909,241,040,000,000,000.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, OTIC beats the other by $222,250,202,909,241,040,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OTIC + SBUX for your $10,000?

OTIC: 50%SBUX: 50%
100% SBUX50/50100% OTIC
Portfolio after 10yr
$131828412946801131520.00M
Annual income
$130,735,413,476,024,150,000,000,000.00/yr
Blended yield
99.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

OTIC
Analyst Ratings
3
Buy
2
Hold
1
Sell
Consensus: Buy
Price Target
$6.00
+70488.2% upside vs current
Range: $6.00 — $6.00
Altman Z
-16.9
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OTIC buys
0
SBUX buys
6
PoliticianChamberTickerTypeAmountDate
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Shelley Moore Capito🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-28
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Sheldon Whitehouse🏛 Senate$SBUX▼ Sell$1,001 - $15,0002026-01-09
Dan Newhouse🏢 House$SBUX▼ Sell$1,001 - $15,0002025-12-11
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$SBUX▲ Buy$15,001 - $50,0002025-09-29
Ro Khanna🏢 House$SBUX▼ Sell$15,001 - $50,0002025-08-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOTICSBUX
Forward yield23529.41%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$263656825893602263040.00M$157.5K
Annual income after 10y$261,470,826,952,048,300,000,000,000.00$65,840.13
Total dividends collected$263512773352864874496.00M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy
Analyst price target$6.00$104.00

Year-by-year: OTIC vs SBUX ($10,000, DRIP)

YearOTIC PortfolioOTIC Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$2,363,641$2,352,941.18$11,107$407.21+$2.35MOTIC
2$522,296,260$519,767,163.60$12,512$626.87+$522.28MOTIC
3$107,898,570,132$107,339,713,133.69$14,366$978.69+$107898.56MOTIC
4$20,839,539,403,669$20,724,087,933,628.63$16,929$1,557.50+$20839539.39MOTIC
5$3,763,094,738,299,595$3,740,796,431,137,668.50$20,658$2,543.80+$3763094738.28MOTIC
6$635,328,756,192,409,300$631,302,244,822,428,800.00$26,406$4,302.22+$635328756192.38MOTIC
7$100,290,713,829,320,920,000$99,610,912,060,195,030,000.00$35,877$7,622.00+$100290713829320.89MOTIC
8$14,802,844,275,710,542,000,000$14,695,533,211,913,168,000,000.00$52,741$14,352.64+$14802844275710542.00MOTIC
9$2,042,989,665,003,715,000,000,000$2,027,150,621,628,704,700,000,000.00$85,676$29,243.03+$2042989665003714816.00MOTIC
10$263,656,825,893,602,270,000,000,000$261,470,826,952,048,300,000,000,000.00$157,513$65,840.13+$263656825893602263040.00MOTIC

OTIC vs SBUX: Complete Analysis 2026

OTICStock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Full OTIC Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this OTIC vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OTIC vs SCHDOTIC vs JEPIOTIC vs OOTIC vs KOOTIC vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.